News | April 22, 2023
CCI approves Berhyanda's acquisition of Suven Pharma
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Clinical studies are expected to start in Q2 2023.
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Subscribe To Our Newsletter & Stay Updated
